Match!
Journal of Psychopharmacology
IF
4.22
Papers
3614
Papers 3663
1 page of 367 pages (3,663 results)
Newest
#1Ju-Chun Pei (NTU: National Taiwan University)H-Index: 6
#2Wei-Li Hung (NTU: National Taiwan University)H-Index: 1
Last.Wen-Sung Lai (NTU: National Taiwan University)H-Index: 14
view all 10 authors...
Background:Compelling animal and clinical studies support the N-methyl-D-aspartate receptor (NMDAR) hypofunction hypothesis of schizophrenia and suggest promising pharmacological agents to ameliora...
#1Parnian Pardis (U of T: University of Toronto)
#2Gary Remington (U of T: University of Toronto)H-Index: 59
Last.Ofer Agid (U of T: University of Toronto)H-Index: 29
view all 5 authors...
Background:It is commonly recommended that a switch to clozapine be implemented in the face of tardive dyskinesia, even if current treatment involves another “atypical” agent. However, reports do i...
#1Zhang Cheng (PKU: Peking University)H-Index: 2
#2Yanbo Yuan (PKU: Peking University)H-Index: 5
Last.Jingping Zhao (CSU: Central South University)H-Index: 33
view all 10 authors...
Purpose:This study aimed to investigate the efficacy and tolerability of aripiprazole, olanzapine and risperidone in first-episode schizophrenia (FES).Methods:The eight-week, open, randomised study...
#1Wei Zheng (Guangzhou Medical University)H-Index: 110
#2Xiao-Min Zhu (Soochow University (Suzhou))H-Index: 4
Last.Yuping Ning (Guangzhou Medical University)H-Index: 11
view all 10 authors...
Objectives:This meta-analysis of randomized controlled trials (RCTs) examined the efficacy and safety of minocycline for three major mental disorders: schizophrenia, bipolar disorder and major depr...
#1Estibaliz Arce (Pfizer)H-Index: 1
#2Rita Balice-Gordon (Pfizer)H-Index: 2
Last.Nicholas DeMartinis (Pfizer)H-Index: 8
view all 9 authors...
Background:PF-06412562 is an orally bioavailable, selective dopamine D1/D5 receptor partial agonist with a non-catechol structure under evaluation for treatment of cognitive impairment in schizophr...
#1Marieke A.G. Martens (University of Oxford)H-Index: 1
#2Angus Antley (University of Oxford)
Last.Elizabeth M. Tunbridge (University of Oxford)H-Index: 24
view all 6 authors...
Background:Virtual reality (VR) is increasingly used to study and treat psychiatric disorders. Its fidelity depends in part on the extent to which the VR environment provides a convincing simulatio...
#1J.I. Cunningham (Alkermes)H-Index: 2
#2David J. Eyerman (Alkermes)H-Index: 2
Last.Mark Namchuk (Alkermes)
view all 7 authors...
Background:Olanzapine, regarded as one of the most efficacious antipsychotic medications for the treatment of schizophrenia, is associated with a high risk of weight gain and metabolic dysfunction....
#1Sean James Fallon (University of Oxford)H-Index: 5
#2Annika Kienast (University of Oxford)H-Index: 2
Last.Masud Husain (University of Oxford)H-Index: 65
view all 6 authors...
Background:Working memory (WM) deficits in neuropsychiatric disorders have often been attributed to altered dopaminergic signalling. Specifically, D2 receptor stimulation is thought to affect the e...
#1Nazanin DoostdarH-Index: 2
#2Eugene Kim ('KCL': King's College London)
Last.Anthony C. Vernon ('KCL': King's College London)H-Index: 16
view all 6 authors...
Background:Cognitive deficits and structural brain changes co-occur in patients with schizophrenia. Improving our understanding of the relationship between these is important to develop improved therapeutic strategies. Back-translation of these findings into rodent models for schizophrenia offers a potential means to achieve this goal.Aims:The purpose of this study was to determine the extent of structural brain changes and how these relate to cognitive behaviour in a sub-chronic phencyclidine r...
12345678910